Market capitalization | GBP161.55b |
Enterprise Value | GBP181.11b |
P/E (TTM) P/E ratio | 28.28 |
EV/FCF (TTM) EV/FCF | 26.59 |
EV/Sales (TTM) EV/Sales | 4.42 |
P/S ratio (TTM) P/S ratio | 3.94 |
P/B ratio (TTM) P/B ratio | 5.32 |
Dividend yield | 2.34% |
Last dividend (FY24) | GBP2.46 |
Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.
32 Analysts have issued a AstraZeneca forecast:
32 Analysts have issued a AstraZeneca forecast:
Mar '25 |
+/-
%
|
||
Revenue | 40,986 40,986 |
15%
15%
|
|
Gross Profit | 33,755 33,755 |
16%
16%
|
|
EBITDA | 12,752 12,752 |
30%
30%
|
EBIT (Operating Income) EBIT | 9,858 9,858 |
42%
42%
|
Net Profit | 5,794 5,794 |
23%
23%
|
In millions GBP.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Head office | United Kingdom |
CEO | Pascal Soriot |
Employees | 94,300 |
Founded | 1992 |
Website | www.astrazeneca.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.